Indian stock news
On June 6, 2026, Sun Pharmaceutical Industries Limited announced that it has received final approval from the USFDA for its first--to--file Abbreviated New Drug Application (ANDA) for a generic version of a blockbuster oncology drug. The company has been granted 180 days of competitive generic exclusivity. The company stated that this approval "marks a significant milestone in our strategy to expand our specialty portfolio and provide affordable treatment options." This development is expected to significantly enhance Sun Pharma's specialty segment revenue in the North American market, which currently accounts for approximately 35% of its global sales.